Pasar al contenido principal

IDENTIFICACION DE UN BIOMARCADOR INTEGRADO DE MIRNA/MRNA PARA EL DIAGNOSTICO TEMPRANO DE LA DEMENCIA CON CUERPOS DE LEWY A PARTIR DE FIRMAS MOLECULARES EN DIFERENTES FUENTES PERIFERICAS

PI18/00276

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease

  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Armengol, Maria P.
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Beyer, Katrin|||0000-0001-8905-1514
Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia, after Alzheimer's disease (AD), and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a seven-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based biosignature, which distinguishes DLB from AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodies

  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Armengol Barnils, Maria del Pilar|||0000-0002-9423-2966
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Beyer, Katrin|||0000-0001-8905-1514
Because of the increasing life expectancy in our society, aging-related neurodegenerative disorders are one of the main issues in global health. Most of these diseases are characterized by the deposition of misfolded proteins and a progressive cognitive decline. Among these diseases, Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are the most common types of degenerative dementia. Although both show specific features, an important neuropathological and clinical overlap between them hampers their correct diagnosis. In this work, we identified molecular biomarkers aiming to improve the misdiagnosis between both diseases. Plasma extracellular vesicles (EVs) -from DLB, AD and healthy controls- were isolated using size-exclusion chromatography (SEC) and characterized by flow cytometry, Nanoparticle Tracking Analysis (NTA) and cryo-electron microscopy. Next Generation Sequencing (NGS) and related bibliographic search was performed and a selected group of EV-associated microRNAs (miRNAs) was analysed by qPCR. Results uncovered two miRNAs (hsa-miR-451a and hsa-miR-21-5p) significantly down-regulated in AD samples respect to DLB patients, and a set of four miRNAs (hsa-miR-23a-3p, hsa-miR-126-3p, hsa-let-7i-5p, and hsa-miR-151a-3p) significantly decreased in AD respect to controls. The two miRNAs showing decreased expression in AD in comparison to DLB provided area under the curve (AUC) values of 0.9 in ROC curve analysis, thus suggesting their possible use as biomarkers to discriminate between both diseases. Target gene analysis of these miRNAs using prediction online tools showed accumulation of phosphorylation enzymes, presence of proteasome-related proteins and genes involved in cell death among others. Our data suggest that plasma-EV associated miRNAs may reflect a differential profile for a given dementia-related disorder which, once validated in larger cohorts of patients, could help to improve the differential diagnosis of DLB versus AD. The online version of this article (10.1186/s40035-019-0169-5) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease

  • Marsal-García, Laura|||0000-0002-6337-1656
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Beyer, Katrin|||0000-0001-8905-1514
  • Urbizu, Aintzane|||0000-0001-8458-1209
  • Arnaldo, Laura|||0000-0003-1654-0573
Lewy body diseases (LBD) including dementia with Lewy bodies (DLB) and Parkinson disease (PD) are characterized by alpha-synuclein pathology. DLB is difficult to diagnose and peripheral biomarkers are urgently needed. Therefore, we analyzed the expression of five alpha-synuclein gene (SNCA) transcripts, SNCAtv1, SNCAtv2, SNCAtv3, SNCA126, and SNCA112, in 45 LBD and control temporal cortex samples and in the blood of 72 DLB, 59 PD, and 54 control subjects. The results revealed overexpression of SNCAtv1 and SNCA112 in DLB, and SNCAtv2 in PD temporal cortices. In DLB blood, diminution of all SNCA transcripts was observed. SNCAtv1 and SNCAtv2 were diminished in PD with disease onset before 70 years. SNCAtv3, driven by its own promoter, showed opposite expression in early DLB and PD, suggesting that its amount may be an early, DLB specific biomarker. Correlation between blood transcript levels and disease duration was positive in DLB and negative in PD, possibly reflecting differences in brain alpha-synuclein aggregation rates associated with differences in disease courses. In conclusion, SNCA transcripts showed a disease-specific increase in the brain and were diminished in blood of LBD patients. SNCAtv3 expression was decreased in early DLB and increased in early PD and could be a biomarker for early DLB diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Alternative platelet activation pathways and their role in neurodegenerative diseases

  • Ferrer Raventós, Paula|||0000-0001-9406-4811
  • Beyer, Katrin|||0000-0001-8905-1514
Purpose of the review: The study of platelets in the context of neurodegenerative diseases is intensifying, and increasing evidence suggests that platelets may play an important role in the pathogenesis of neurodegenerative disorders. Therefore, we aim to provide a comprehensive overview of the role of platelets and their diverse activation pathways in the development of these diseases. Recent findings: Platelets participate in synaptic plasticity, learning, memory, and platelets activated by exercise promote neuronal differentiation in several brain regions. Platelets also contribute to the immune response by modulating their surface protein profile and releasing pro- and anti-inflammatory mediators. In Alzheimer's disease, increased levels of platelet amyloid precursor protein raise the production of amyloid-beta peptides promoting platelet activation, triggering at the same time amyloid-beta fibrillation. In Parkinson's disease, increased platelet α-synuclein is associated with elevated ROS production and mitochondrial dysfunction. In this review, we revise different platelet activation pathways, those classically involved in hemostasis and wound healing, and alternative activation pathways recently described in the context of neurodegenerative diseases, especially in Alzheimer's disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obtaining miRNA from Saliva-Comparison of Sampling and Purification Methods

  • Urbizu, Aintzane|||0000-0001-8458-1209
  • Arnaldo, Laura|||0000-0003-1654-0573
  • Beyer, Katrin|||0000-0001-8905-1514
The use of saliva as a biomarker source has advantages over other biofluids and imaging techniques, and miRNAs are ideal biomarker candidates. They are involved in numerous cellular processes, and their altered expression suggests that miRNAs play a crucial regulatory role in disease development. We wanted to find an easily reproducible and executable miRNA-obtaining methodology suitable for quantification. Three commercial miRNA extraction kits (mirVana, Nucleospin and miRNeasy) and three saliva collectors (50 mL tubes, Salimetrics and Oragene) were tested. Several features, including RNA quality and technical parameters, were evaluated. The expression of five synthetic spike-in controls and seven saliva-miRNAs was analyzed independently and grouped by the collectors and the extraction kits. The combination of Oragene and miRNeasy assured the most sensitive detection of all seven saliva miRNAs. Testing different combinations of saliva collectors and RNA purification kits permitted the establishment of combinations for different uses. The results of our study highlight that optimization of resources for biomarker studies is possible after careful planning of each study.